N

NFX

Venture firm funding pre-seed startups

Overview

NFX is a venture capital firm that funds early-stage startups at pre-seed and seed rounds. It invests capital in young companies and provides hands-on support, including strategic guidance, introductions to mentors and potential customers, and help with fundraising. Unlike generalist investors, NFX concentrates exclusively on the earliest stages, helping founders move from idea to validated business and aiming to build category-leading companies that deliver returns for its investors.

Work here?Claim your company

About NFX

Simplify's Rating
Why NFX is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Data & AnalyticsConsultingVenture CapitalEnterprise Software

Company Size

51-200

Company Stage

N/A

Total Funding

$6B

Headquarters

San Francisco, CA

Founded

2015

Get referred to NFX

See people who can refer or advise you

Simplify Jobs

Simplify's take

What believers are saying

  • September 2026 self-funding gives NFX speed and flexibility in volatile AI markets.
  • October 2026 AI-heavy operating model can lower costs and widen deal coverage.
  • June 2026 Altro Health shows NFX still leads fast-growing, category-creating health startups.

What critics are saying

  • October 2026 staff were told to find new jobs after NFX ended external fundraising.
  • Shrinking to personal capital after 2027 cuts competitiveness against Andreessen Horowitz and Sequoia.
  • If AI tools fail to replace fund-scale sourcing, NFX becomes a smaller advisory shop.

What makes NFX unique

  • September 2026 self-funding lets NFX write $100K-$3M checks with no LP constraints.
  • NFX has backed about 42 unicorns since 2017, giving founders credible pattern recognition.
  • Gigi Levy-Weiss and James Currier combine Israel, Silicon Valley, and AI-native investing experience.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$6B

Above

Industry Average

Funded Over

0 Rounds

Company News

LinkedIn
Oct 31st, 2026
🎉 2024: A Year of Growth, Innovation, and Milestones for caVos 🎉 As the year comes to a close, we’re thrilled to reflect on the incredible journey we’ve had in 2024. Here’s a look back at some of… | Ohad Tarcic

🎉 2024: A Year of Growth, Innovation, and Milestones for caVos 🎉 As the year comes to a close, we’re thrilled to reflect on the incredible journey we’ve had in 2024. Here’s a look back at some of the highlights that made this year unforgettable: 🚀 Successful Funding Round We closed an oversubscribed funding round of $3.3M! This milestone was made possible with the support of incredible investors, including aMoon Fund, Entrée Capital , NFX, Tal Ventures, Alumni Ventures, and the Israel Innovation Authority רשות החדשנות (IIA). We are deeply grateful to Yaron Daniely, Yael Gruenbaum-Cohen , Vered Gigi, PhD , Prof. Yuval Tabach, Ran Achituv, Omri Amirav-Drory, Miriam Shtilman Lavsovski , and Ron Levin for their invaluable guidance and contributions throughout this process. 📖 Read more: https://lnkd.in/djACvFfB 🌟 Recognized as a Most Promising Startup We were honored to be featured in The Marker’s prestigious list of the 20 most promising startups of 2024. This recognition fuels our commitment to push boundaries and innovate in the biotech space. 📖 Read more: https://lnkd.in/dMKwuSRr 💡 A Growing Team, New Labs, and Offices This year marked a period of significant growth as we expanded our talented team and moved into our new state-of-the-art labs and offices. These new spaces will set up the stage for our next phase of breakthroughs. 🔬 Advancing Science with Therapeutic mRNA Agents We began developing our first therapeutic mRNA agents—a major step forward in our mission to deliver novel precision therapeutics. This work reflects our dedication to advancing science and impacting human health, starting with cancer eradication. Thank you to everyone—our team, investors, and partners—who made this year so extraordinary. Here’s to an even brighter 2025, as we continue to harness the power of evolution to transform healthcare. Stay tuned—our journey is just getting started! 🚀

LinkedIn
Oct 26th, 2026
#cybersecurity #exposuremanagement #forestay | Deborah Pittet

Excited to celebrate this major achievement for VERITI! Congratulations to Adi Ikan and Oren Koren and rest of the team on the successful acquisition by Check Point Software. Your dedication and vision have truly set a new standard in the threat exposure management industry. It’s been a privilege to collaborate with you, and I look forward to seeing your future accomplishments! #Cybersecurity #ExposureManagement #Forestay

U.S. Securities and Exchange Commission
Oct 25th, 2026
EDGAR Filing Documents for 0001791749-21-000001

EIN.: 841790390 | State of Incorp.: DE | Fiscal Year End: 1231Type: D | Act: 33 | File No.: 021-403917 | Film No.: 211037821

U.S. Securities and Exchange Commission
Oct 25th, 2026
EDGAR Filing Documents for 0001886318-21-000001

EIN.: 843536371 | State of Incorp.: DE | Fiscal Year End: 1231Type: D | Act: 33 | File No.: 021-416223 | Film No.: 211314074

U.S. Securities and Exchange Commission
Oct 25th, 2026
EDGAR Filing Documents for 0001866760-21-000005

EIN.: 863732853 | State of Incorp.: DE | Fiscal Year End: 1231Type: D | Act: 33 | File No.: 021-415529 | Film No.: 211301625

Recently Posted Jobs

Sign up to get curated job recommendations

There are no jobs for NFX right now.

Find jobs on Simplify and start your career today

We update NFX's jobs every few hours, so check again soon!Browse all jobs